Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Annual Report · 10-K

AngioDynamics, Inc.

ANGONASDAQEQUITYCurrent

Annual Report

Filed Aug 3, 2023Accepted Aug 3, 2023, 5:16 PM EDTCIK 1275187Accession 0001628280-23-027335
Share

Company context

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients. The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, v isit www.angiodynamics.com.

Current securities

Recent company filings

  1. 10-K/A filingSep 29, 2026
  2. 144 filingJul 30, 2026
  3. 4 filingJul 22, 2026
  4. 4 filingJul 22, 2026
  5. 4 filingJul 22, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗